Home > Boards > US OTC > Medical - Healthcare >

BioRestorative Therapies Inc. (BRTXQ)

BRTXQ RSS Feed
Add BRTXQ Price Alert      Hide Sticky   Hide Intro
Moderator: Walker, WHITTENHALLJR, cash4, Homebrew, Pennyes
Search This Board: 
Last Post: 4/6/2020 8:31:17 PM - Followers: 93 - Board type: Free - Posts Today: 0

DALE BROADRICK

INVESTS APPX $ 2,000,000.00 IN THE LAST 2

MONTHS
IN THE OPEN MARKET!

IS HE STILL ADDING?
 
 

https://www.otcmarkets.com/stock/BRTX/quote

 
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
 
BRTX #1 Most Shorted stock by Finra

https://otce.finra.org/otce/marketStatistics/top100Issues


 

BRTXQ

BioRestorative Therapies, Inc.

http://www.biorestorative.com/

BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.

Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.

Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes.

Product Candidates

 

BRTX-100

In the United States, 25 million people suffer from chronic lower back pain each year, half of whom have or will be diagnosed with disc degeneration. Current treatments–including opioid pain relievers, steroid injections, and physical therapy–simply manage pain, ignoring the root causes of the problem.  Many patients reluctantly progress to surgical interventions, which are highly invasive and clinical outcomes have demonstrated limited, if any, therapeutic benefits.

BRTX-100 is a novel product to treat damaged, degenerating discs, and is anticipated to be safer, cheaper, and more effective upon a single treatment. Specifically, BRTX-100 is an autologous stem cell product that uses your own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process.

We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

If you are an individual interested in participating as a subject in this clinical trial or you are a physician, clinic or other service looking to provide services for the trial, please email trials@biorestorative.com.

Product Candidates

BRTX-100

In the United States, 25 million people suffer from chronic lower back pain each year, half of whom have or will be diagnosed with disc degeneration. Current treatments–including opioid pain relievers, steroid injections, and physical therapy–simply manage pain, ignoring the root causes of the problem.  Many patients reluctantly progress to surgical interventions, which are highly invasive and clinical outcomes have demonstrated limited, if any, therapeutic benefits.

BRTX-100 is a novel product to treat damaged, degenerating discs, and is anticipated to be safer, cheaper, and more effective upon a single treatment. Specifically, BRTX-100 is an autologous stem cell product that uses your own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process.

We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

If you are an individual interested in participating as a subject in this clinical trial or you are a physician, clinic or other service looking to provide services for the trial, please email trials@biorestorative.com.

ThermoStem®

Obesity, diabetes, hypertension, hyperlipidemia and certain heart related disorders, have long been seen as contributing to a pandemic in the US—40% of Americans are obese; 30% have type 2 diabetes or pre-diabetes, and half of Americans have at least one major risk factor for heart disease.

To target obesity and metabolic disorders, we’ve developed our ThermoStem® program that uses brown adipose-derived (“brown fat”) stem cells to generate new brown fat tissue. BioRestorative Therapies was one of the first companies to identify and publish data about this novel stem cell population. This population of fat is known to burn, rather than store, energy.  Elevated levels of brown fat have been demonstrated to increase metabolism and facilitate weight loss.

Initial preclinical research indicates that increased amounts of activated brown fat in the body may be responsible for additional caloric burning, as well as reduced glucose and lipid levels. Further, researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Leadership

 
 

Mark Weinreb

CEO & President
Mark Weinreb is an early pioneer in the field of regenerative medicine and cellular therapy and has significant experience in running public companies.

He previously served as the Chief Executive Officer and Chairman of the Board of Directors of Phase III Medical, Inc. where he orchestrated the acquisition of an adult stem cell collection company that became NeoStem, Inc. (now Caladrius Biosciences, Inc. – NASDAQ: CLBS), a public international biopharmaceutical company engaged in, among other things, adult stem cell-related science.  From June 2006 through October 2009, Mr. Weinreb served as President and a director of NeoStem.

In 1976, Mr. Weinreb joined Bio Health Laboratories, Inc., a state-of-the-art medical diagnostic laboratory providing clinical testing services for physicians, hospitals, and other medical laboratories. As an owner and Chief Operating Officer, he oversaw all technical and business facets, including finance and laboratory science technology. Bio Health Laboratories was acquired by Enzo Biochem (NYSE: ENZ).

Mr. Weinreb received a Bachelor of Arts degree from Northwestern University and a Master of Science degree in Medical Biology from C.W. Post, Long Island University.

 
 

Francisco Silva

Chief Scientist & VP, R&D

Francisco Silva joined BRT in April 2011 and is Vice President of Research and Development. Mr. Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs.

Mr. Silva previously served as Chief Executive Officer of two companies engaged in the commercialization of human-based biologics for both research and therapeutic applications.

From 2003 to 2007, Mr. Silva was Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell-based platforms.  He was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms.

Mr. Silva has taught courses in biology, anatomy

 

Mandy Clyde, PHR

VP, Operations

Mandy Clyde has been Vice President of Operations for BioRestorative Therapies since 2009 and is an original founding member of the Company. Ms. Clyde is responsible for the overall corporate operations for BioRestorative including public relations, human resources and corporate stock issuance. She holds a Professional in Human Resources designation and has over 17 years of experience working in the health care sector.

Prior to her role at BioRestorative, Ms. Clyde held positions within PRIME Education, LLC, an accredited provider of medical and professional education. She oversaw onsite educational programs throughout the U.S. for major pharmaceutical sponsors including Novartis, Pfizer and Sanofi and was responsible for designing and implementing new company initiatives on Needs Assessment, Outcomes Analysis and Reporting, and Transformational Learning. Ms. Clyde has experience in content editing for educational programs and has been a contributing author on both medical and professional topics.

Ms. Clyde also has experience in clinical settings as both a surgical coordinator and optometric technician for prominent ophthalmology and optometry practices in Florida including the Rand Eye Institute and Lenscrafters. She received a degree in Biology with a pre-medicine concentration from Mercyhurst University in Pennsylvania.

 

Bob Paccasassi

VP, Quality & Compliance

Bob Paccasassi joined BioRestorative Therapies in September 2015 as its Vice President of Quality and Compliance operations.   Mr. Paccasassi has over 20 years of experience in highly regulated product operations, with specific expertise in GMP (large and small molecule) clinical and commercial quality assurance and regulatory compliance leadership roles.

Prior to joining BioRestorative Therapies, Mr. Paccasassi was the Director of Quality Systems (GMP) at Merck KGaA (Darmstadt, Germany), the oldest pharmaceutical and chemical company in the world with over 50,000 employees and operations in 66 countries worldwide.  Within this role, Mr. Paccasassi was responsible for leading the ongoing development and implementation of the Corporate Quality Unit’s global GMP policies, processes and directives.

Mr. Paccasassi held key quality and compliance management roles at EMD Serono, Biogen Idec, Millennium Pharmaceuticals and Regeneron Pharmaceuticals.

Mr. Paccasassi holds a Master’s degree in Business Administration (MBA) from Johnson & Wales University and a Bachelor of Science degree in Medical Technology / Biology from the University of Rhode Island.

 

Scientific Advisors

 

Wayne Marasco, MD, PhDChairman, Scientific Advisory BoardView >
Jason Lipetz, MDChairman, Disc Advisory BoardView >
Wayne Olan, MDClinical Director of Regenerative Disc/Spine ProgramView >
Gerard A. Malanga, MDDisc Advisory MemberView >
Christopher Plastaras, MDDisc Advisory MemberView >
Harvinder Sandhu, MDDisc Advisory MemberView >
Joy Cavagnaro, PhDMemberView >
Naiyer Imam, MD, MScMemberView >

 
Board
Mark WeinrebChairmanView >
Jeffrey RadovDirectorView >
Paul Jude TonnaDirectorView 
Robert CatellDirectorView >

 
NEWS/PRESS RELEASES
http://www.biorestorative.com/ir/

CONTACT
Address:40 Marcus DriveSuite OneMelville, NY 11747(631) 760-8100
 
Entry into a Material Definitive Agreement.

On March 20, 2020, BioRestorative Therapies, Inc. (the “Company”) entered into a stalking horse asset purchase agreement (the “Asset Purchase Agreement”) with Phoenix Cell Group Holdings LLC, an affiliate of John M. Desmarais (the “Purchaser”), to acquire substantially all of the Company’s assets (the “Sale”).
Pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, the purchase price is $500,000 in cash, subject to adjustment (the “Cash Component”), plus the Credit Bid Amount, the Expense Reimbursement and the aggregate Cure Amounts (as such terms are defined in Asset Purchase Agreement). The Asset Purchase Agreement is subject to certain closing conditions, including certain orders being entered by the Bankruptcy Court (as defined in Item 1.03 below) and other customary closing conditions detailed in the Asset Purchase Agreement.
The Asset Purchase Agreement remains subject to higher or better offers, as well as approval of the Bankruptcy Court. The Asset Purchase Agreement provides for a breakup fee equal to 2% of the sum of the Cash Component, the Credit Bid (exclusive of amounts loaned in 2016 and 2017 by Mr. Desmarais and his affiliate) and the Cure Amounts and also provides for reimbursement of up to $250,000 of the Purchaser’s expenses incurred in connection with the Asset Purchase Agreement and the DIP Loan Agreement (as defined in Item 1.03 below), each of which is payable upon certain termination events in accordance with the terms of the Asset Purchase Agreement.
The closing of the Sale is scheduled to be held on the second business day following satisfaction of the conditions set forth in the Asset Purchase Agreement.
The foregoing description of the Asset Purchase Agreement and the transactions contemplated thereby, including the Sale, does not purport to be complete and is qualified in its entirety by reference to the text of the Asset Purchase Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference.
Also, see Item 1.03 for a discussion of the DIP Loan Agreement.
Item 1.03
Bankruptcy or Receivership.

Chapter 11 Filing
On March 20, 2020 (the “Petition Date”), the Company filed a voluntary petition commencing a case under chapter 11 of title 11 of the U.S. Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Eastern District of New York (the “Bankruptcy Court”). The Company’s chapter 11 case (the “Chapter 11 Case”) is being administered under the caption, In re: BioRestorative Therapies, Inc., Case No. 8-20-71757. The Company will continue to operate its business as a “debtor-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court.

John Desmarais is the founding partner of Desmarais LLP.

John M. Desmarais
Partner, New York
PHONE: 212-351-3420 FAX: 212-351-3401

EDUCATION
New York University School of Law, J.D., 1988

Manhattan College, B.Ch.E., 1985, magna cum laude, Chemical Engineering Medal
ADMISSIONS
1989, New York

1990, District of Columbia

2018, California

Registered to practice before the United States Patent and Trademark Office



https://www.desmaraisllp.com/john-desmarais

After practicing in the area of intellectual property litigation and counseling for several years at Fish & Neave, in 1992, he left private practice to serve as an Assistant United States Attorney in the Southern District of New York, where for three years he tried criminal jury trials for the federal government. After leaving the government, Mr. Desmarais returned to Fish & Neave and to the practice of intellectual property litigation. In 1997, he joined the New York office of Kirkland & Ellis as a partner, and later became head of the firmwide Intellectual Property Litigation Practice. From 2004-2009, he also served as a member of Kirkland's Firm Management Committee. After 13 years at Kirkland, Mr. Desmarais left to found Desmarais LLP, an Intellectual Property trial boutique that specializes in jury trials for plaintiffs and defendants and focuses on alternative fee structures.

On the plaintiff's side, Mr. Desmarais's recent $82.5 Million win for IBM against Groupon on four patents the jury found to be willfully infringed was widely covered in the press and resulted in his selection by The American Lawyer as "Litigator of the Week."

Mr. Desmarais's $1.5 billion win for Alcatel-Lucent against Microsoft resulted in one of the largest plaintiff's jury verdicts in a patent infringement action. This win has been profiled in the following articles: “Microsoft Hit With $1.52 Billion Verdict in MP3 Suit,”

 

Share Structure

Market Cap Market Cap
327,841
03/27/2020
Authorized Shares
2,000,000,000
03/12/2020
Outstanding Shares
1,639,203,270
03/12/2020
Restricted
13,980,199
03/12/2020
Unrestricted
1,625,223,071
03/12/2020
Held at DTC
1,625,185,217
03/12/2020
Float
6,979,170
04/22/2019

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
WARNING !!

SHAREHOLDERS WILL LOSE 100 %
on the Day Shares Are Cancelled !

From the Company....
"...Based on the values for the Company’s business contemplated by the Asset Purchase Agreement referred to herein, the Company expects that existing Company stockholders will receive no recovery at the end of the Chapter 11 Case,
 consistent with legal priorities...."

BRTXQ
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BRTX News: Current Report Filing (8-k) 02/20/2020 04:36:33 PM
BRTX News: Current Report Filing (8-k) 02/14/2020 05:48:44 PM
BRTX News: Current Report Filing (8-k) 02/11/2020 05:31:45 PM
BRTX News: Current Report Filing (8-k) 02/07/2020 04:40:09 PM
BRTX News: Current Report Filing (8-k) 01/31/2020 05:23:39 PM
PostSubject
#8593  Sticky Note No, that is false. He only bid trader59 03/29/20 08:28:56 PM
#8558  Sticky Note BRTX #1 Most Shorted stock by Finra cash4 03/28/20 03:44:24 PM
#8042  Sticky Note Great talking with company 20 min ago.. He EmptyBones 03/04/20 01:46:58 PM
#8662   Volume is getting better every day. cash4 04/06/20 08:31:17 PM
#8660   That’s not how it works. The creditors’ trader59 04/06/20 07:10:11 AM
#8659   That cash4 is exactly how I feel things badshah 04/06/20 06:19:33 AM
#8658   They filed for bankruptcy to remove the debt, cash4 04/06/20 02:47:03 AM
#8657   What, exactly, "remains to be seen?" The company trader59 04/05/20 11:10:05 PM
#8656   Exactly I'm not heavenly invested so if i Rougejoe 04/05/20 10:45:30 PM
#8655   Remains to be seen, the stock is not cash4 04/05/20 09:30:03 PM
#8653   Once again, in the company's own financial reports, trader59 04/05/20 05:03:31 PM
#8652   From the 3/20 filing... badshah 04/05/20 04:19:50 PM
#8651   badshah 04/05/20 04:05:27 PM
#8650   AMENDED AND RESTATED STALKING HORSE ASSET PURCHASE AGREEMENT cash4 04/05/20 03:08:11 PM
#8649   I do not have a big investment here cash4 04/05/20 02:53:37 PM
#8648   Gonna respond anyway... trader59 04/05/20 10:18:25 AM
#8647   Cash4...Patent number: 10597638...If this patent was issued on badshah 04/05/20 09:01:13 AM
#8646   $brtx $.0002 Taurus69 04/04/20 05:36:42 PM
#8645   It isn’t different for shareholders. The price trader59 04/04/20 10:23:20 AM
#8644   How is the "Amended and Restated Asset Purchase badshah 04/04/20 06:39:00 AM
#8643   A bit closer....Meaningless intra-day order processing volume. Just Homebrew 04/03/20 09:18:09 PM
#8642   gotcha 6of1 04/03/20 02:40:19 PM
#8641   Sure, a bit over 2 grand so far. trader59 04/02/20 10:06:53 PM
#8640   https://www.otcshortreport.com/company/BRTX Historical Short Volume Data for BRTX cash4 04/02/20 05:35:39 PM
#8639   the page that comes up on your link 6of1 04/02/20 04:48:50 PM
#8638   Again, you're 100% Wrong. Nothing about "shorts" there. Homebrew 04/01/20 08:33:12 PM
#8637   Follow my link and you'll see the real cash4 04/01/20 08:18:45 PM
#8636   Multi-Millionaires like John M. Desmarais do not invest StemCellStockGuy 03/31/20 10:41:20 AM
#8635   BRTX...ZERO Shorts per FINRA...Some posts misunderstand FINRA info, Homebrew 03/30/20 10:35:44 PM
#8634   4X the volume today, just getting warmed up. cash4 03/30/20 08:10:59 PM
#8633   Must not want to create waves yet. $10,000 cash4 03/30/20 02:58:10 PM
#8632   Sure, a bit over 2 grand so far. trader59 03/30/20 02:57:28 PM
#8631   Ok..I could care less..I'm grown I can make cash4 03/30/20 02:52:35 PM
#8630   Every OTC play is bankrupt and in debt cash4 03/30/20 02:50:18 PM
#8629   It isn't opinion. It says so right trader59 03/30/20 02:49:42 PM
#8627   The offer of $500k for the assets includes trader59 03/30/20 02:39:58 PM
#8626   Article is from November, well ahead of the trader59 03/30/20 02:39:10 PM
#8625   Patents Assigned to BIORESTORATIVE THERAPIES, INC. cash4 03/30/20 02:29:54 PM
#8624   Regarding the patent issued in Australia of BRT-100 cash4 03/30/20 02:21:48 PM
#8623   Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Healt cash4 03/30/20 02:15:05 PM
#8622   No, that isn't. The underlined portion clearly trader59 03/30/20 01:10:51 PM
#8621   this is standard Chap 11 language, and you badshah 03/30/20 12:57:38 PM
#8620   The 8K from the company says: trader59 03/30/20 12:47:30 PM
#8619   Cash4...thanks for posting all those happenings in the badshah 03/30/20 12:45:18 PM
#8618   Higher volume today than yesterday, double the shares cash4 03/30/20 12:37:23 PM
#8617   cash4...You the man...many company's stock is worthless after badshah 03/30/20 07:24:30 AM
#8615   Ok..I guess I'll lose $500, way less than cash4 03/29/20 10:44:11 PM
#8614   The stock of a bankrupt company will trade trader59 03/29/20 10:39:35 PM
#8613   Bankruptcy 101: trader59 03/29/20 10:38:36 PM
#8612   Plenty companies in bankruptcy that trade,..that's not something cash4 03/29/20 10:29:21 PM
#8611   Ok,..I'll take my chances, to me it seems cash4 03/29/20 10:26:37 PM
#8610   I only post what I can prove, not cash4 03/29/20 10:23:06 PM
#8609   The shareholders are always last in line when trader59 03/29/20 09:59:43 PM
PostSubject